Search results
'Extraordinary' study results offer new hope for advanced lung cancer patients being treated with...
USA TODAY via Yahoo News· 2 years agoPatients with advanced lung cancer had a better chance at survival when their treatment combined...
Merck (MRK) Gets CHMP Nod for Keytruda in Adjuvant Lung Cancer
Zacks via Yahoo Finance· 9 months agoMerck's (MRK) Keytruda gets a positive CHMP opinion, recommending the approval of the drug for the...
Merck's lung cancer drug combo fails trial in setback for new therapy class
Reuters via AOL· 7 months agoMerck's experimental anti-TIGIT drug vibostolimab in combination with its approved therapy Keytruda...
Advanced Lung Cancer and Immunotherapy
Verywell Health via Yahoo News· 9 months agoImmunotherapy is a newer class of treatment for lung and other cancers. It primes the body’s natural immune system to fight back against cancer....
Merck's (MRK) Keytruda-Lynparza Combo Fails 2nd Lung Cancer Study
Zacks via Yahoo Finance· 3 months agoMerck's attempt to use the Keytruda-Lynparza combination in certain non-small cell lung cancer...
Merck could keep its patent edge by shifting Keytruda cancer drug to a simple shot
Reuters via Yahoo News· 2 years agoU.S. drugmaker Merck & Co hopes to patent a new formulation of its $20 billion cancer immunotherapy...
GSK's (GSK) PD-1 Inhibitor Drug Meets Lung Cancer Study Goal
Zacks via Yahoo Finance· 2 years agoGSK's (GSK) mid-stage study, evaluating the combination of its cancer drug Jemperli with...
FDA approves new Bristol Myers drug for lung cancer
BioPharma Dive via Yahoo Finance· 7 months agoAcquired via a $4 billion biotech buyout, Augtyro is one of an array of new products the pharma hopes will offset patent expirations for current top...
U.S. FDA approves Mirati's lung cancer drug
Reuters via Yahoo News· 2 years ago(Reuters) -The U.S. Food and Drug Administration approved Mirati Therapeutics Inc's lung cancer drug adagrasib, the company said on Monday, sending its...
Mirati Wins FDA Approval For Amgen-Rivaling Cancer Drug As Wild Stock Swing Continues
Investor's Business Daily· 2 years agoThe Food and Drug Administration approved Mirati Therapeutics' rival to Amgen's lung cancer drug,...
